19099 Background: The G+C combination is one of the most widely used treatments for NSCLC. Aimed to enhance DI and reduce toxicity, the original 4-week schedule has been generally modified into a 3-week schedule, decreasing the C dose from 100 to 75–80 mg/sqm and increasing the G dose was from 1000 mg/sqm to 1250 mg/sqm. Others have postponed the C administration from day 1 or 2 to day 8 or 15, in the 4-week schedule, but in the 3-week schedule C administered on day 1 or 2 may hamper the 8th day G dose, due to toxicity. This report presents our experience with a modified 3-week schedule, that we have adopted into the daily clinical practice. Methods: Our pts were treated with G (1000 mg/sqm) on days 1,8 and C on day 8 (100 mg/sqm until January 2004: 75 pts, or 75 mg/sqm from January 2004: 85 pts). The GCSF use was allowed, according to the pts clinical needs. The toxicity was recorded according to the NCIC-criteria. Results: from October, 2000 to October, 2007 a consecutive series of 160 stage IIIa-IV NSCLC pts (median age 61.5 yrs, range 31- 77) received CG as induction therapy for locally advanced (62 pts) or as palliative treatment for metastatic disease (98 pts). Overall, the pts received 630 chemotherapy courses (median 3, range 2–6, for locally advanced and 4, range 2–9, for metastatic pts). The median DI was 87% (range 34–100). Considering the 8th-day dose, 16% of the treatments were delayed due to hematologic toxicities, while in 17% of the cases a GCSF priming after day 1 was necessary. Grade 3–4 hematological toxicities (per pts) were: anemia 3.7%, leukopenia 7.5%, neutropenia 46.8%, thrombocytopenia 5%. In pts with locally advanced disease, a 71% response rate (RR) and 14 mos of median OS were observed. In metastatic pts the RR was 53% and the median OS was 11 mos. Conclusions: it appears from our experience, that our modified 3-weeks regimen, compared to others 3-weeks CG schedules, has provided a similar DI, is equally active and tolerated but with a better hematologic toxicity profile in terms of anemia and thrombocytopenia. No significant financial relationships to disclose.